At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Post-Mkt 02-26 16:33:41 EST
2.18
-0.14
-6.03%
盘后2.18
+0.000.00%
16:10 EST
High2.34Low2.12Vol538.71K
Open2.29D1 Closing2.32Amplitude9.48%
Mkt Cap80.73MTradable Cap61.78MTotal Shares37.03M
T/O1.19MT/O Rate1.90%Tradable Shares28.34M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MAIA Biotechnology published a 2026 Letter to Shareholders
TIPRANKS  ·  02-24 21:50
MAIA Biotechnology published a 2026 Letter to Shareholders
Maia Biotechnology Publishes February 2026 Shareholder Letter
Reuters  ·  02-24 21:46
Maia Biotechnology Publishes February 2026 Shareholder Letter
Maia Biotechnology Announces Availability of 2026 Shareholder Letter
Reuters  ·  02-24 21:45
Maia Biotechnology Announces Availability of 2026 Shareholder Letter
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
GlobeNewswire  ·  02-24 21:45
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
MAIA Biotechnology outlines 2026 goals for ateganosine program
TIPRANKS  ·  01-21
MAIA Biotechnology outlines 2026 goals for ateganosine program
MAIA Biotechnology highlights milestones, catalysts for FY26
TIPRANKS  ·  01-20
MAIA Biotechnology highlights milestones, catalysts for FY26
Maia Biotechnology Reports Strong 2025 Progress and Outlines 2026 Clinical Milestones for Ateganosine
Reuters  ·  01-20
Maia Biotechnology Reports Strong 2025 Progress and Outlines 2026 Clinical Milestones for Ateganosine
MAIA Biotechnology Highlights Strategy in New Investor Presentation
TIPRANKS  ·  01-14
MAIA Biotechnology Highlights Strategy in New Investor Presentation
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
Reuters  ·  01-12
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
GlobeNewswire  ·  2025-12-24
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
Reuters  ·  2025-12-23
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
Director Ngar Yee Louie Acquires Common Shares of Maia Biotechnology Inc
Reuters  ·  2025-12-23
Director Ngar Yee Louie Acquires Common Shares of Maia Biotechnology Inc
MAIA Biotechnology Announces $1.51 Million Private Placement
GlobeNewswire  ·  2025-12-17
MAIA Biotechnology Announces $1.51 Million Private Placement
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
GlobeNewswire  ·  2025-12-12
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
Maia Biotechnology Announces First Patient Dosed in Thio-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  2025-12-11
Maia Biotechnology Announces First Patient Dosed in Thio-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
Maia Biotechnology Executives Acquire 182,445 Shares in Insider Buying Spree
Reuters  ·  2025-12-11
Maia Biotechnology Executives Acquire 182,445 Shares in Insider Buying Spree
Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer
Reuters  ·  2025-12-11
Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
Reuters  ·  2025-12-10
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
BRIEF-Maia Biotechnology Announces Open Market Purchases By CEO And Directors
Reuters  ·  2025-12-01
BRIEF-Maia Biotechnology Announces Open Market Purchases By CEO And Directors
Maia Biotechnology Announces Open Market Purchases by CEO and Directors
THOMSON REUTERS  ·  2025-12-01
Maia Biotechnology Announces Open Market Purchases by CEO and Directors

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--